Patent ID: 11965038
Assignee: ZYMEDI CO., LTD.
Field: Measurement (Instruments)
Classification: CPC C  A  G | IPC C

Claim 0:
1. A method for treating an immune cell migration-related disease in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising an antibody binding specifically to an epitope containing the sequence of SEQ ID NO: 117 in the N-terminus of lysyl-tRNA synthetase (KRS) or an antigen binding fragment thereof as an effective ingredient,
wherein the antibody or antigen binding fragment thereof comprises:
(a) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 3 or SEQ ID NO: 151, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 11, SEQ ID NO: 13 or SEQ ID NO: 15;
(b) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 or SEQ ID NO: 23, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 15: or
(c) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 21, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5 or SEQ ID NO: 25; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, SEQ ID NO: 27, or SEQ ID NO: 29, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 15,
wherein the immune cell migration-related disease is a cardiovascular disease, a fibrotic disease, an inflammatory disease, or Alport syndrome.